Suppr超能文献

血管紧张素转换酶2(ACE2)参与新型冠状病毒肺炎(COVID-19)所致心血管损伤的可能机制及研究进展:综述

The possible mechanism and research progress of ACE2 involved in cardiovascular injury caused by COVID-19: a review.

作者信息

Luo Dan, Bai Mengzhe, Zhang Wei, Wang Junnan

机构信息

Department of Cardiology, Second Hospital of Jilin University, Changchun, Jilin, China.

出版信息

Front Cardiovasc Med. 2024 May 27;11:1409723. doi: 10.3389/fcvm.2024.1409723. eCollection 2024.

Abstract

ACE2 is the earliest receptor discovered to mediate the entry of SARS-CoV-2. In addition to the receptor, it also participates in complex pathological and physiological processes, including regulating the RAS system, apelin, KKS system, and immune system. In addition to affecting the respiratory system, viral infections also interact with cardiovascular diseases. SARS-CoV-2 can directly invade the cardiovascular system through ACE2; Similarly, cardiovascular diseases such as hypertension and coronary heart disease can affect ACE2 levels and exacerbate the disease, and ACE2 dysregulation may also be a potential mechanism for long-term acute sequelae of COVID-19. Since the SARS CoV-2 epidemic, many large population studies have tried to clarify the current focus of debate, that is, whether we should give COVID-19 patients ACEI and ARB drug treatment, but there is still no conclusive conclusion. We also discussed potential disease treatment options for ACE2 at present. Finally, we discussed the researchers' latest findings on ACE2 and their prospects for future research.

摘要

血管紧张素转换酶2(ACE2)是最早被发现介导严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进入细胞的受体。除作为受体外,它还参与复杂的病理生理过程,包括调节肾素-血管紧张素系统(RAS系统)、apelin、激肽释放酶-激肽系统(KKS系统)及免疫系统。病毒感染除影响呼吸系统外,还与心血管疾病相互作用。SARS-CoV-2可通过ACE2直接侵入心血管系统;同样,高血压和冠心病等心血管疾病可影响ACE2水平并加重病情,而ACE2失调也可能是冠状病毒病(COVID-19)长期急性后遗症的潜在机制。自SARS-CoV-2疫情以来,许多大规模人群研究试图阐明当前争论的焦点,即是否应给予COVID-19患者血管紧张素转换酶抑制剂(ACEI)和血管紧张素Ⅱ受体阻滞剂(ARB)药物治疗,但仍未得出确凿结论。我们还讨论了目前针对ACE2的潜在疾病治疗方案。最后,我们讨论了研究人员关于ACE2的最新发现及其未来研究前景。

相似文献

1
The possible mechanism and research progress of ACE2 involved in cardiovascular injury caused by COVID-19: a review.
Front Cardiovasc Med. 2024 May 27;11:1409723. doi: 10.3389/fcvm.2024.1409723. eCollection 2024.
2
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
Curr Cardiol Rep. 2020 Apr 14;22(5):31. doi: 10.1007/s11886-020-01291-4.
5
Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator.
Acta Pharm Sin B. 2021 Jan;11(1):1-12. doi: 10.1016/j.apsb.2020.10.006. Epub 2020 Oct 13.
7
Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
PLoS Comput Biol. 2020 Oct 8;16(10):e1008235. doi: 10.1371/journal.pcbi.1008235. eCollection 2020 Oct.
8
SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications.
J Mol Cell Cardiol. 2020 Jul;144:47-53. doi: 10.1016/j.yjmcc.2020.04.031. Epub 2020 Apr 30.
9
Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury.
Biomed Pharmacother. 2021 Apr;136:111193. doi: 10.1016/j.biopha.2020.111193. Epub 2021 Jan 5.
10
Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
J Med Virol. 2020 Jul;92(7):726-730. doi: 10.1002/jmv.25785. Epub 2020 Apr 5.

引用本文的文献

本文引用的文献

1
SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril.
Antiviral Res. 2023 Jul;215:105636. doi: 10.1016/j.antiviral.2023.105636. Epub 2023 May 18.
2
Emerging roles of SARS-CoV-2 Spike-ACE2 in immune evasion and pathogenesis.
Trends Immunol. 2023 Jun;44(6):424-434. doi: 10.1016/j.it.2023.04.001. Epub 2023 Apr 6.
4
Angiotensin-converting enzyme 2-at the heart of the COVID-19 pandemic.
Cell. 2023 Mar 2;186(5):906-922. doi: 10.1016/j.cell.2023.01.039. Epub 2023 Feb 2.
5
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.
Nature. 2023 Mar;615(7950):134-142. doi: 10.1038/s41586-022-05594-0. Epub 2022 Dec 5.
6
SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly.
J Exp Med. 2023 Feb 6;220(2). doi: 10.1084/jem.20220906. Epub 2022 Nov 15.
7
SARS-CoV-2 infection downregulates myocardial ACE2 and potentiates cardiac inflammation in humans and hamsters.
Am J Physiol Heart Circ Physiol. 2022 Dec 1;323(6):H1262-H1269. doi: 10.1152/ajpheart.00578.2022. Epub 2022 Nov 11.
8
The Expanding Arsenal of Cytotoxic T Cells.
Front Immunol. 2022 Apr 20;13:883010. doi: 10.3389/fimmu.2022.883010. eCollection 2022.
9
Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical Trial.
JAMA Netw Open. 2022 Mar 1;5(3):e222735. doi: 10.1001/jamanetworkopen.2022.2735.
10
Post-acute COVID-19 syndrome.
Eur Respir Rev. 2022 Mar 9;31(163). doi: 10.1183/16000617.0185-2021. Print 2022 Mar 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验